8-K/A: Exicure Acquires GPCR Therapeutics USA, Enters License Agreement to Advance Novel Cancer Therapies

Exicure, Inc. has acquired GPCR Therapeutics USA and entered into a license agreement to further develop and commercialize GPCR's technologies, including a promising Phase 2 clinical trial for blood cancer.

Summary

• Exicure, Inc. has acquired GPCR Therapeutics USA from GPCR Therapeutics Inc., a Korean corporation.
• The acquisition was completed concurrently with the execution of a Share Purchase Agreement on January 19, 2025.
• Exicure also entered into a License and Collaboration Agreement with GPCR to develop and commercialize GPCR's technologies.
• The agreement includes milestone payments to GPCR based on clinical trial achievements, marketing authorizations, and net sales, as well as a recurring royalty payment of at least 10% of net sales.
• GPCR USA has an ongoing Phase 2 clinical trial for blood cancer patients using a combination of G-CSF, GPC-100 (Burixafor), and propranolol.
• Interim data from 10 patients shows promising results for stem cell mobilization, with median times to neutrophil and platelet engraftment at 11 and 14 days respectively.
• GPCR USA plans to complete the administration of GPC-100 to 20 patients by the end of April and announce the clinical trial results by September.
• The company is also considering a double-blind clinical trial comparing Plerixafor with GPC-100.
• Research suggests the combination of GPC-100 and propranolol may enhance CAR-T cell response rates.

Sentiment

Score: 7

Explanation: The document presents a positive development with the acquisition and collaboration agreement, along with promising clinical trial data. However, there are also risks and uncertainties associated with the company's future and financial position.

Positives

• The acquisition of GPCR Therapeutics USA provides Exicure with a promising clinical-stage asset.
• The License and Collaboration Agreement with GPCR provides a framework for future development and commercialization.
• The Phase 2 clinical trial for blood cancer has shown promising interim results.
• The combination therapy allows for same-day administration of mobilizing agent and leukapheresis, which is an advantage over some existing treatments.
• The treatment regimen exhibited excellent safety profiles in patients receiving the new front line blood cancer drug, Daratumumab.
• The potential for enhanced CAR-T cell response rates could expand Exicure's pipeline for cell and gene therapies.

Negatives

• The License and Collaboration Agreement includes milestone payments and a recurring royalty payment of at least 10% of net sales, which could impact profitability.
• The company is still in the early stages of development and faces risks associated with clinical trials and regulatory approvals.
• Exicure is exploring strategic alternatives to maximize stockholder value, which may indicate financial challenges.

Risks

• The accuracy of projections, targets, or plans related to the acquisition and clinical trials is uncertain.
• There is a risk of listing deficiencies and potential delisting from Nasdaq.
• The company faces risks associated with clinical trials, regulatory approvals, and commercialization of new therapies.
• The company's financial position and ability to fund future development activities are not explicitly detailed.

Future Outlook

Exicure is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. The company will continue to develop and commercialize GPCR's technologies, including the ongoing Phase 2 clinical trial. The company is also considering a double-blind clinical trial comparing Plerixafor with GPC-100.

Management Comments

• Dr. Cardarelli stated that two additional patients will receive treatment in January 2025.
• Dr. Cardarelli mentioned that positive results from the GPC-100 trial could have a beneficial impact on attracting additional investment and enhancing corporate value.
• Dr. Cardarelli suggested that in the future, it will be essential to prioritize discussions with various partners based on the likelihood of success and high return on investment.
• Dr. Cardarelli concluded that if the hypotheses presented to GPCR USA are validated, there may be potential G-Protein Coupled Receptor targets that could be applicable to various diseases.

Industry Context

This acquisition and collaboration agreement highlight the ongoing interest in developing novel therapies for blood cancers and the potential of G-Protein Coupled Receptor targets. The focus on stem cell mobilization and CAR-T cell therapies aligns with current trends in the biotechnology industry.

Comparison to Industry Standards

• The median times to neutrophil and platelet engraftment of 11 and 14 days respectively are slightly less than what has been observed for standard of care, suggesting a potential improvement.
• The fast kinetics of mobilization with burixafor, allowing for same-day administration of mobilizing agent and leukapheresis, differentiates it from FDA-approved treatments like plerixafor or motixafortide, which require overnight pre-treatment.
• The ongoing clinical trial is focused on a combination therapy, which is a common approach in cancer treatment to improve efficacy and overcome resistance.
• The potential for enhanced CAR-T cell response rates aligns with the growing interest in cell and gene therapies for cancer treatment.

Stakeholder Impact

• Shareholders may benefit from the acquisition and potential for future growth.
• Employees of GPCR USA may experience changes in their roles and responsibilities.
• Patients with blood cancer may benefit from the development of new therapies.
• The company's suppliers and partners may be impacted by the acquisition and collaboration agreement.

Next Steps

• GPCR USA will complete the administration of GPC-100 to 20 patients by the end of April 2025.
• GPCR USA will conduct follow-up observations until July 2025.
• GPCR USA aims to announce the clinical trial results by September 2025.
• The company is considering a double-blind clinical trial comparing Plerixafor with GPC-100.
• Exicure will continue to explore strategic alternatives to maximize stockholder value.

Key Dates

Keywords

Exicure, GPCR Therapeutics, GPCR USA, Share Purchase Agreement, License Agreement, Clinical Trial, Blood Cancer, Stem Cell Mobilization, GPC-100, Burixafor, CAR-T, Hematopoietic Stem Cell Transplantation, Leukapheresis